MYCOBUTIN

This brand name is authorized in Austria, Australia, Canada, Estonia, Hong Kong, Ireland, Israel, Japan, Netherlands, New Zealand, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug MYCOBUTIN contains one active pharmaceutical ingredient (API):

1 Rifabutin UNII 1W306TDA6S - RIFABUTIN

Rifabutin is an antibiotic used to treat tuberculosis and prevent and treat Mycobacterium avium complex. Read about Rifabutin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
MYCOBUTIN Capsules	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J04AB04	Rifabutin	J Antiinfectives for systemic use → J04 Antimycobacterials → J04A Drugs for treatment of tuberculosis → J04AB Antibiotics
Discover more medicines within J04AB04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 6195C, 9541E
Country: CA	Health Products and Food Branch	Identifier(s): 02063786
Country: EE	Ravimiamet	Identifier(s): 1654635
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 40846
Country: HK	Department of Health Drug Office	Identifier(s): 38559
Country: IE	Health Products Regulatory Authority	Identifier(s): 64723
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 3115
Country: JP	医薬品医療機器総合機構	Identifier(s): 6169001M1026
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 43060
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 6723
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8681308151094
Country: US	FDA, National Drug Code	Identifier(s): 0013-5301
Country: ZA	Health Products Regulatory Authority	Identifier(s): Z/20.1.1/395